Biomarkers

Relationship between risk and protective factors and clinical features of Parkinson’s disease

Risk and protective factors of PD development may influence PD clinical features. This finding may represent the first step in the development of new preventive approaches able to delay disease onset and mitigate the extent of clinical manifestations. CLICK TO REVIEW

Relationship between risk and protective factors and clinical features of Parkinson’s disease Read More »

Hyperbaric Oxygen Therapy Improves Parkinson’s Disease by Promoting Mitochondrial Biogenesis via the SIRT-1/PGC-1α Pathway

Hyperbaric oxygen therapy (HBOT) has been suggested as a potential adjunctive therapy for Parkinson’s disease (PD). PD is a neurodegenerative disease characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). The aim of this study was to investigate the protective mechanisms of HBOT on neurons and motor function in

Hyperbaric Oxygen Therapy Improves Parkinson’s Disease by Promoting Mitochondrial Biogenesis via the SIRT-1/PGC-1α Pathway Read More »

Parkinson’s Disease: A Prionopathy?

The principal pathogenic event in Parkinson’s disease is characterized by the conformational change of α-synuclein, which form pathological aggregates of misfolded proteins, and then accumulate in intraneuronal inclusions causing dopaminergic neuronal loss in specific brain regions. Over the last few years, a revolutionary theory has correlated Parkinson’s disease and other neurological disorders with a shared

Parkinson’s Disease: A Prionopathy? Read More »

Phenoconversion Risk Factors in Rapid Eye Movement Sleep Behavior Disorder

A multicenter cohort of idiopathic/isolated rapid eye movement sleep behavior disorder (iRBD) was studied to determine any predictive factors for α-synuclein–related neurodegenerative illnesses. At the start of the study, patients with iRBD from 12 different sites were given a complete assessment for potential environmental and lifestyle risk factors using a standardized questionnaire. Patients were then

Phenoconversion Risk Factors in Rapid Eye Movement Sleep Behavior Disorder Read More »

Gastrointestinal involvement in Parkinson’s disease: pathophysiology, diagnosis, and management

Growing evidence suggests an increasing significance for the extent of gastrointestinal tract (GIT) dysfunction in Parkinson’s disease (PD). Most patients suffer from GIT symptoms, including dysphagia, sialorrhea, bloating, nausea, vomiting, gastroparesis, and constipation during the disease course. The underlying pathomechanisms of this α-synucleinopathy play an important role in disease development and progression, i.e., early accumulation

Gastrointestinal involvement in Parkinson’s disease: pathophysiology, diagnosis, and management Read More »

Alpha-synuclein as a Potential Biomarker for Parkinson’s Disease and Other
Synucleinopathies: Gaps, Challenges, and Opportunities

Parkinson’s disease (PD), the second most common progressive neurodegenerative disease,develops and progresses for 10-15 years before the clinical diagnostic symptoms of thedisease are manifested. Furthermore, several aspects of PD pathology overlap with otherneurodegenerative diseases (NDDs) linked to alpha-synuclein aggregation, also calledsynucleinopathies. Therefore, there is an urgent need to discover and validate earlydiagnostic and prognostic markersthat

Alpha-synuclein as a Potential Biomarker for Parkinson’s Disease and Other
Synucleinopathies: Gaps, Challenges, and Opportunities
Read More »

Short-Chain Fatty Acids Modulate Healthy Gut Microbiota Composition and Functional Potential

Many studies have focused on the metabolic capacity of human gut microbiota to produce short-chain fatty acids and subsequent effects on host physiology. Given scarce data on how SCFAs produced by gut bacteria participate in cross-feeding to influence community structure and function, we evaluated the potential of SCFAs to modulate human gut microbiota in vitro.

Short-Chain Fatty Acids Modulate Healthy Gut Microbiota Composition and Functional Potential Read More »

Exploiting Caenorhabditis elegans to discover human gut microbiota-mediated intervention strategies in protein conformational diseases

Age-dependent protein-conformational diseases (PCDs), such as Alzheimer’s disease (AD), Parkinson’s disease (PD), or amyotrophic lateral sclerosis (ALS), are characterized by misfolding and aggregation of metastable proteins present within the proteome of the affected individual. Recent evidence supports the notion that bacteria and bacterial products may be affecting the stability of these culprit host proteins and

Exploiting Caenorhabditis elegans to discover human gut microbiota-mediated intervention strategies in protein conformational diseases Read More »

Predictors of RBD progression and conversion to synucleinopathies

There is a variety of potential biomarkers for monitoring disease progression and predicting iRBD conversion into synucleinopathies. A combined multimodal biomarker model could offer a more sensitive and specific tool. Further longitudinal studies are warranted to iRBD as a high-risk population for early neuroprotective interventions and disease-modifying therapies. CLICK TO REVIEW

Predictors of RBD progression and conversion to synucleinopathies Read More »

ORAL BUTYRATE AND MICROBIOTA-TARGETED TREATMENTS FOR PARKINSON’S
DISEASE: EFFICACY STUDIES IN TRANSGENIC MICE.

Current pharmacological treatments for Parkinson’s disease (PD) provide relief for motorsymptoms but fail to alleviate prevalent non-motor symptoms (NMS)- such as gastrointestinal(GI) dysfunction which often occurs before the development of motor symptoms. Strategies toslow the progression of PD have been proposed, but so far none has proven successful. PDpatients display changes in gut microbiome composition

ORAL BUTYRATE AND MICROBIOTA-TARGETED TREATMENTS FOR PARKINSON’S
DISEASE: EFFICACY STUDIES IN TRANSGENIC MICE.
Read More »